Targeted CXCL1 and PD-L1 bispecific nano antibody and application thereof
By constructing a bispecific nanoantibody targeting CXCL1 and PD-L1, the problems of low response rate and immune escape of CRC patients to PD-1/PD-L1 inhibitors were solved, and efficient CRC treatment effect was achieved.
Patent Information
- Application Number
- CN202511012235.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-22
- Publication Date
- 2025-10-17
- Estimated Expiration
- 2045-07-22
AI Technical Summary
Colorectal cancer (CRC) patients have a low response rate to PD-1/PD-L1 inhibitors, and immune escape mechanisms lead to drug resistance. Traditional antibodies have deficiencies in penetrability and immunogenicity, and existing treatments are difficult to effectively reshape the tumor microenvironment.
Develop bispecific nanoantibodies targeting CXCL1 and PD-L1, utilize the high affinity and multi-target properties of nanoantibodies, identify CXCL1 and PD-L1 through linkers, construct nanoantibodies that can effectively block the signals of both at the same time, and express them in combination with vectors and host cells.
It achieves highly specific binding to CXCL1 and PD-L1, prevents drug resistance caused by immune escape, and provides a new idea for CRC treatment that is suitable for more patients.
Smart Images

Figure CN120795165A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application belongs to the field of antibody engineering and bioengineering technology, and particularly relates to a bispecific nanobody targeting CXCL1 and PD-L1 and application thereof. BACKGROUND
[0002] The information disclosed in this Background section is only for the purpose of increasing the understanding of the general background of the application and does not necessarily constitute an admission or a recognition that the information forms part of the prior art that is already known in any country in the world.
[0003] Colorectal cancer (CRC) is a malignant tumor with high morbidity and mortality, and the treatment of patients in the advanced stage still faces severe challenges. Although immune checkpoint inhibitors (ICIs), especially monoclonal antibodies targeting the PD-1 / PD-L1 pathway, have brought innovation to tumor treatment, their efficacy has significant limitations in the field of CRC. Most CRC patients are microsatellite stable (MSS), and the response rate to PD-1 / PD-L1 monotherapy is extremely low. Studies have found that the chemokine CXCL1 secreted by CRC cells recruits myeloid-derived suppressor cells (MDSCs) and promotes the formation of neutrophil extracellular traps (NETs), etc., which, in cooperation with the PD-L1-mediated immunosuppressive signal, together shape a highly immunosuppressive tumor microenvironment (TME), which not only inhibits the function of CD8+ T cells, but also is a key mechanism leading to resistance to PD-1 / PD-L1 inhibitors. Targeting the CXCL1-CXCR2 axis to reshape the immune microenvironment and combining with PD-L1 targeting to block T cell inhibition are expected to break through the bottleneck of CRC immunotherapy.
[0004] Traditional full-length antibodies have deficiencies in penetration and immunogenicity, and the miniaturization and multi-targeting of antibody drugs have become an important development trend. Nanobodies (VHH) have become a promising therapeutic antibody form due to their small molecular weight, strong penetration, high degree of humanization, good stability, and low immunogenicity. At the same time, bispecific antibodies (BsAb) can simultaneously target two key antigens or signaling pathways, have the potential to synergize, overcome drug resistance, enhance targeting, and reduce toxic side effects. Using the nanobody platform that is easy to engineer, a bispecific nanobody that can efficiently block CXCL1 and PD-L1 at the same time can not only integrate the excellent properties of nanobodies and the synergistic advantages of dual-targeting combination therapy, but also is expected to provide a more potential new means of CRC treatment. SUMMARY
[0005] In order to solve the problems in the prior art, the target CXCL1 and PD-L1 bispecific nanobody and the application thereof are provided, the target CXCL1 and PD-L1 bispecific nanobody provided by the application has an affinity of 1.08 nM to chemotactic factor CXCL1 and an affinity of 1.09 nM to programmed cell death-ligand 1 (PD-L1). The target CXCL1 and PD-L1 bispecific nanobody constructed by the application effectively reduces the influence of fusion expression on the affinity of the antibody, and can simultaneously target two antigens, thereby effectively preventing the drug resistance of patients to antibody treatment caused by immune escape.
[0006] In order to achieve the above-mentioned object, the technical scheme of the application is as follows: In a first aspect, the application provides a target CXCL1 and PD-L1 bispecific nanobody, comprising at least one nanobody recognizing a target CXCL1 and one nanobody recognizing a target PD-L1, wherein the nanobody monomers are connected by a linker. The amino acid sequences of CDR1-CDR3 of the nanobody recognizing the target CXCL1 are selected from any one of the following combinations: Combination 1, wherein the amino acid sequences of CDR1-CDR3 are respectively shown as SEQ ID NO. 1-SEQ ID NO. 3; Combination 2, wherein the amino acid sequences of CDR1-CDR3 are respectively shown as SEQ ID NO. 4-SEQ ID NO. 6; Combination 3, wherein the amino acid sequences of CDR1-CDR3 are respectively shown as SEQ ID NO. 7-SEQ ID NO. 9; The amino acid sequences of CDR1-CDR3 of the nanobody recognizing the target PD-L1 are respectively shown as SEQ ID NO. 10-SEQ ID NO. 12.
[0007] CRC is a malignant tumor originating from the mucosal epithelium of the colon or rectum, and its occurrence and development are closely related to the imbalance of the immune microenvironment and the dysfunction of T cells. Patients often show local symptoms such as hematochezia, changes in bowel habits (such as alternating diarrhea and constipation), anemia, and weight loss. In the late stage, due to the failure of immune surveillance, liver and lung metastasis or peritoneal dissemination may occur. With the change of residents' lifestyle and environmental factors, the disease shows a trend of younger onset, and the problem of treatment resistance caused by tumor immune escape mechanism is increasingly prominent. Patients experience long-term surgical trauma, chemotherapy side effects, and immune exhaustion, significantly increasing the physical and mental burden.
[0008] The immune checkpoint inhibitor (ICI) opens up a new way for the treatment of tumors. PD-L1 is expressed in CRC, and its overexpression is associated with poor prognosis, but the effect of anti-PD-1 / PD-L1 monoclonal antibody treatment on CRC is not ideal. Studies have shown that CXCL1 promotes the infiltration of tumor-associated neutrophils (TANs), inhibits CD8 + T cells, thereby promoting the immune escape of tumor cells. When anti-PD-1 monoclonal antibody treatment is resistant, the number of TANs increases, and the infiltration of CD8 + T cells decreases, and inhibiting the CXCL1 signal can restore the efficacy of PD-1 antibody therapy. Therefore, combined blocking of PD-L1 and CXCL1 may provide an effective treatment for CRC patients. In this regard, the present application develops a bispecific nanobody targeting CXCL1 and PD-L1, which has important significance in the treatment of pancreatic cancer.
[0009] The bispecific nanobody targeting CXCL1 and PD-L1 provided by the present application has extremely strong specificity and affinity for PD-L1 and CXCL1, can effectively prevent drug resistance of patients to antibody therapy caused by immune escape, is suitable for more patients, and provides a new idea for the treatment of CRC.
[0010] In some embodiments of the present application, the amino acid sequence of the linker is as shown in SEQ ID NO. 13.
[0011] In some embodiments of the present application, the amino acid sequence of the bispecific nanobody targeting CXCL1 and PD-L1 is as shown in any one of SEQ ID NO. 14 to SEQ ID NO. 21.
[0012] In a second aspect of the present application, a nucleic acid molecule encoding the bispecific nanobody targeting CXCL1 and PD-L1 is provided.
[0013] In some embodiments of the present application, the nucleic acid molecule includes a coding nucleic acid capable of being translated into the above-mentioned nanobody due to codon degeneracy, and the coding nucleic acid is not limited to DNA or RNA. Preferably, the coding nucleic acid is DNA, including cDNA, genomic DNA or artificially synthesized DNA; the DNA can be single-stranded or double-stranded, and can be a coding strand or a non-coding strand.
[0014] In a third aspect of the present application, an expression vector including the nucleic acid molecule is provided.
[0015] In some embodiments of the present application, the expression vector includes but is not limited to a bacterial plasmid, a bacteriophage, a yeast plasmid, a plant cell virus, a mammalian cell virus or other vectors. Preferably, the expression vector is a bacterial plasmid or a yeast plasmid.
[0016] In a fourth aspect of the present application, a host cell transformed or transfected with the expression vector is provided.
[0017] In some embodiments of the present application, the host cell is a plant cell or a microbial cell. Preferably, the host cell is a microbial cell. Further preferably, E. coli is used as the host cell.
[0018] In a fifth aspect of the present application, the present application further provides a conjugate or a complex comprising the chemically or biologically labeled bispecific nanobody targeting CXCL1 and PD-L1 and an acceptable adjuvant or carrier.
[0019] In some embodiments of the present application, the chemical label is an isotope, an immunotoxin and / or a chemical drug; and the biological label is biotin, avidin or an enzyme label.
[0020] In a sixth aspect of the present application, based on the above research, the present application further provides use of the bispecific nanobody targeting CXCL1 and PD-L1 or the conjugate or the complex in the preparation of an anti-tumor drug.
[0021] In some embodiments of the present application, the anti-tumor drug contains at least one functional component, and further comprises a pharmaceutically acceptable carrier. Preferably, the pharmaceutically acceptable carrier is water, a buffered aqueous solution, an isotonic salt solution such as PBS (phosphate buffered saline), glucose, mannitol, dextrose, lactose, starch, magnesium stearate, cellulose, magnesium carbonate, 0.3% glycerol, hyaluronic acid, ethanol or polyalkylene glycol such as polypropylene glycol, triglycerides, etc. The type of the pharmaceutically acceptable carrier depends, inter alia, on whether the anti-tumor drug according to the present application is formulated for oral, nasal, intradermal, subcutaneous, intramuscular or intravenous administration. In some embodiments of the present application, the tumor includes, but is not limited to, colorectal cancer.
[0022] In a seventh aspect of the present application, the present application further provides use of the bispecific nanobody targeting CXCL1 and PD-L1 or the conjugate or the complex in the preparation of a cytokine detection reagent and / or a kit.
[0023] In an eighth aspect of the present application, based on the above research, the present application further provides a cytokine detection reagent comprising the bispecific nanobody targeting CXCL1 and PD-L1 or the conjugate or the complex and an acceptable adjuvant and / or carrier.
[0024] The present application has the following beneficial effects: The PD-L1 / CXCL1-targeting bispecific Nanobody provided by the present invention has a unique structure, which enables the bispecific Nanobody to specifically recognize and bind to both CXCL1 and PD-L1. This can effectively prevent the resistance of patients to antibody therapy caused by immune escape, making it applicable to more patients and providing a new approach to CRC treatment. This bispecific Nanobody targeting PD-L1 / CXCL1 can simultaneously target two antigens, with an affinity of 1.08 nM for CXCL1 and 1.09 nM for PD-L1, showing highly specific binding activity. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] The accompanying drawings, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.
[0026] Figure 1 The mechanism of action of a bispecific nanobody targeting PD-L1 / CXCL1 constructed based on the Fc region of human IgG1; Figure 2 This is a diagram showing the purification results of a bispecific nanobody targeting PD-L1 / CXCL1. M: protein marker; 1-6: 2C-KN, KN-2C, 12D-KN, KN-12D, 3E-KN, and KN-3E, respectively; Figure 3 Figure 1 shows the purification results of the bispecific antibodies KN-2C-Fc and 12D-KN-Fc targeting PD-L1 / CXCL1. M: Protein Marker; 1: KN-2C-Fc, 2: 12D-KN-Fc; Figure 4 SPR sensorgram of the interaction between bispecific nanobody and PD-L1; Figure 5 SPR sensorgram of the interaction between the bispecific nanobody and CXCL1; Figure 6 SPR sensorgrams of the interactions between the bispecific antibodies KN-2C-Fc and 12D-KN-Fc and CXCL1 (A) and PD-L1 (B). DETAILED DESCRIPTION
[0027] The application discloses a bispecific nanobody targeting CXCL1 and PD-L1 and application, and those skilled in the art can refer to the content of the application, and appropriately improve process parameters to realize. It should be particularly pointed out that all similar replacements and changes are obvious to those skilled in the art, and they are regarded as being included in the application. The method and application of the application have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the method and application described herein without departing from the content, spirit and scope of the application, to realize and apply the technical solution of the application.
[0028] The application provides a bispecific nanobody targeting CXCL1 and PD-L1, a preparation method and application thereof.
[0029] Specifically, The bispecific nanobody targeting CXCL1 and PD-L1 comprises at least one nanobody recognizing a target point CXCL1 and one nanobody recognizing a target point PD-L1, and the nanobodies are connected through a linker; The amino acid sequences of CDR1-CDR3 of the nanobody recognizing the target point CXCL1 are selected from any one of the following combinations: Combination 1, the amino acid sequences of CDR1-CDR3 are respectively shown as SEQ ID NO. 1-SEQ ID NO. 3; Combination 2, the amino acid sequences of CDR1-CDR3 are respectively shown as SEQ ID NO. 4-SEQ ID NO. 6; Combination 3, the amino acid sequences of CDR1-CDR3 are respectively shown as SEQ ID NO. 7-SEQ ID NO. 9; The amino acid sequences of CDR1-CDR3 of the nanobody recognizing the target point PD-L1 are respectively shown as SEQ ID NO. 10-SEQ ID NO. 12.
[0030] The amino acid sequence of the linker is shown as SEQ ID NO. 13.
[0031] The amino acid sequence of the bispecific nanobody targeting CXCL1 and PD-L1 is shown as any one of SEQ ID NO. 14-SEQ ID NO. 21.
[0032] The application further provides application of the bispecific nanobody targeting CXCL1 and PD-L1 in preparation of an antitumor drug.
[0033] The tumor comprises colorectal cancer.
[0034] The application also provides use of the above-mentioned targeted CXCL1 and PD-L1 bispecific nanobody in preparation of a cytokine detection reagent and / or kit.
[0035] The sequences involved in the application are as follows: Nanobody 2C recognizing target CXCL1: CDR1 region amino acid sequence: GRTFSSY (SEQ ID NO. 1) CDR2 region amino acid sequence: SESGGF (SEQ ID NO. 2) CDR3 region amino acid sequence: DFKPTYYSGRHNPTEADFGS (SEQ ID NO. 3) Nanobody 12D recognizing target CXCL1: CDR1 region amino acid sequence: GRAFSIY (SEQ ID NO. 4) CDR2 region amino acid sequence: SRGGGS (SEQ ID NO. 5) CDR3 region amino acid sequence: DISPTPYYKDYAWAS (SEQ ID NO. 6) Nanobody 3E recognizing target CXCL1: CDR1 region amino acid sequence: GRTFGRY (SEQ ID NO. 7) CDR2 region amino acid sequence: SWSGDN (SEQ ID NO. 8) CDR3 region amino acid sequence: DSSPTPFWTVGGWRY (SEQ ID NO. 9) Nanobody KN recognizing target PD-L1: CDR1 region amino acid sequence: GKMSSRR (SEQ ID NO. 10) CDR2 region amino acid sequence: LTTSGS (SEQ ID NO. 11) CDR3 region amino acid sequence: DSFEDPTCTLVTSSGAFQY (SEQ ID NO. 12) Amino acid sequence of linker: GGGGSGGGGSGGGGS (SEQ ID NO. 13) Amino acid sequence of bispecific nanobody targeting PD-L1 / CXCL1 constructed based on anti-HSA nanobody: 2C-KN: DVQLQESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISESGGFTHYADSVKGRFTISRDNTKNTVYLQMNSLKPEDTAVYYCAADFKPTYYSGRHNPTEADFGSWGQGTQVTVSSGGGGSGGGGSGGGGSQVQLVESGGGLVQPGGSLRLSCAASGKMSSRRCMAWFRQAPGKERERVAKLLTTSGSTYLADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAADSFEDPTCTLVTSSGAFQYWGQGTLVTVSSHHHHHH (SEQ ID NO. 14) KN-2C: QVQLVESGGGLVQPGGSLRLSCAASGKMSSRRCMAWFRQAPGKERERVAKLLTTSGSTYLADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAADSFEDPTCTLVTSSGAFQYWGQGTLVTVSSGGGGSGGGGSGGGGSDVQLQESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISESGGFTHYADSVKGRFTISRDNTKNTVYLQMNSLKPEDTAVYYCAADFKPTYYSGRHNPTEADFGSWGQGTQVTVSSHHHHHH (SEQ ID NO. 15) 12D-KN: DVQLQESGGGLVQAGGSLNLSCAASGRAFSIYGMAWFRQAPGKKRDFIAAISRGGGSTFYGDSVLGRFTISRDDAKNTAYLHMNSLKPEDTAVYYCAADISPTPYYKDYAWASWGQGTQVTVSSGGGGSGGGGSGGGGSQVQLVESGGGLVQPGGSLRLSCAASGKMSSRRCMAWFRQAPGKERERVAKLLTTSGSTYLADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAADSFEDPTCTLVTSSGAFQYWGQGTLVTVSSHHHHHH (SEQ ID NO. 16) KN-12D: QVQLVESGGGLVQPGGSLRLSCAASGKMSSRRCMAWFRQAPGKERERVAKLLTTSGSTYLADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAADSFEDPTCTLVTSSGAFQYWGQGTLVTVSSGGGGSGGGGSGGGGSDVQLQESGGGLVQAGDSLRLSCAASGRTFGRYAMGWFRQSPGKVREFVGGISWSGDNTQYADSVKGRFTISRDNAKNTVYLQMNSLIPEDTAVYYCAADSSPTPFWTVGGWRYWGQGTQVTVSSHHHHHH (SEQ ID NO. 17) 3E-KN: DVQLQESGGGLVQAGDSLRLSCAASGRTFGRYAMGWFRQSPGKVREFVGGISWSGDNTQYADSVKGRFTISRDNAKNTVYLQMNSLIPEDTAVYYCAADSSPTPFWTVGGWRYWGQGTQVTVSSGGGGSGGGGSGGGGSQVQLVESGGGLVQPGGSLRLSCAASGKMSSRRCMAWFRQAPGKERERVAKLLTTSGSTYLADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAADSFEDPTCTLVTSSGAFQYWGQGTLVTVSSHHHHHH (SEQ ID NO. 18) KN-3E: QVQLVESGGGLVQPGGSLRLSCAASGKMSSRRCMAWFRQAPGKERERVAKLLTTSGSTYLADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAADSFEDPTCTLVTSSGAFQYWGQGTLVTVSSGGGGSGGGGSGGGGSDVQLQESGGGLVQAGDSLRLSCAASGRTFGRYAMGWFRQSPGKVREFVGGISWSGDNTQYADSVKGRFTISRDNAKNTVYLQMNSLIPEDTAVYYCAADSSPTPFWTVGGWRYWGQGTQVTVSSHHHHHH (SEQ ID NO. 19) Amino acid sequence of a bispecific nanobody targeting PD-L1 / CXCL1 constructed based on the Fc region of human IgGl (P01857): KN-2C-Fc: QVQLVESGGGLVQPGGSLRLSCAASGKMSSRRCMAWFRQAPGKERERVAKLLTTSGSTYLADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAADSFEDPTCTLVTSSGAFQYWGQGTLVTVSSGGGGSGGGGSGGGGSDVQLQESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAAISESGGFTHYADSVKGRFTISRDNTKNTVYLQMNSLKPEDTAVYYCAADFKPTYYSGRHNPTEADFGSWGQGTQVTVSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO. 20) 12D-KN-Fc: DVQLQESGGGLVQAGGSLNLSCAASGRAFSIYGMAWFRQAPGKKRDFIAAISRGGGSTFYGDSVLGRFTISRDDAKNTAYLHMNSLKPEDTAVYYCAADISPTPYYKDYAWASWGQGTQVTVSSGGGGSGGGGSGGGGSQVQLVESGGGLVQPGGSLRLSCAASGKMSSRRCMAWFRQAPGKERERVAKLLTTSGSTYLADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAADSFEDPTCTLVTSSGAFQYWGQGTLVTVSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO. 21) Amino acid sequence of the antigen: PD-L1: FTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNER (SEQ ID NO. 22) CXCL1: MARAALSAAPSNPRLLRVALLLLLLVAAGRRAAGASVATELRCQCLQTLQGIHPKNIQSVNVKSPGPHCAQTEVIATLKNGRKACLNPASPIVKKIIEKMLNSDKSN (SEQ ID NO. 23) The targeting PD-L1 / CXCL1 bispecific nanobody has a unique structure, so that the targeting PD-L1 / CXCL1 bispecific nanobody has specific recognition and binding capacity to CXCL1 and PD-L1. The targeting PD-L1 / CXCL1 bispecific nanobody can simultaneously target two antigens, and the affinity to CXCL1 reaches 1.08 nM, and the affinity to PD-L1 reaches 1.09 nM, and has high specific binding activity.
[0036] The nanobody and raw materials and reagents used in the application thereof provided by the application can be purchased from the market.
[0037] In order to enable those skilled in the art to more clearly understand the technical solutions of the present application, the technical solutions of the present application will be described in detail below in combination with specific examples.
[0038] Example 1. Preparation of a bispecific nanobody targeting CXCL1 and PD-L1 1. Cell lines and production strains The preparation of the PD-L1 and CXCL1 antigens in the present application, and the preparation of the bispecific nanobody targeting PD-L1 / CXCL1 based on the Fc region of human IgG1 (P01857) all use the HEK-293F cell line.
[0039] The human embryonic kidney cells HEK-293F (RRID: CVCL_6642) are obtained from the American Cell Culture Center. All human cell lines have passed the STR analysis verification. Mycoplasma contamination is excluded in these cell lines.
[0040] The HEK-293F cells are placed in a 5% CO2 constant temperature incubator, and incubated at 37°C and 120 rpm constant temperature shaking. When subculturing, first count the cells and observe the cell viability, and select high viability cells with a density of 3-6x10 6 6x10 6 6x10 6 6x10 6 The flask is placed in a 5% CO2 constant temperature incubator, and incubated at 37°C and 120 rpm constant temperature shaking for 10 min before transfection.
[0041] Transfect 200 mL cell suspension, prepare a 15 mL sterile centrifuge tube, a 50 mL sterile centrifuge tube. In one of them, add 10 mL transfection medium and 200 μg sterile plasmid DNA, gently blow and mix; take another centrifuge tube, add 10 mL transfection medium and 1 mL transfection reagent, gently blow and mix; transfer all the liquid in the centrifuge tube containing the transfection reagent to the centrifuge tube containing the plasmid, gently blow and mix; prepare the plasmid-carrier complex at room temperature for 10 minutes; remove the cells from the constant temperature shaker, add the prepared plasmid-carrier complex, and return to the CO2 constant temperature shaker for shaking culture. Add 1 mL 293 cell protein expression enhancer and 4 mL nutrient additive 24 hours after transfection, add 50 mL fresh culture medium 4 days after transfection, and collect the fermentation broth 7 days after transfection.
[0042] The nanobodies in the application are all expressed by Trans B (DE3) expression bacteria.
[0043] The DH5α competent cells used for plasmid cloning and the Trans B competent cells used for nanobody expression are purchased from Beijing Zoman Biotech Co., Ltd.
[0044] Transfect the constructed expression plasmid into Trans B (DE3) competent cells, inoculate the engineering bacteria into a 5 mL LB liquid culture medium test tube, the inoculation amount is 1%, the ampicillin dosage is one thousandth, and the culture is carried out in a constant temperature shaker at 37℃, 220 rpm for about 8 hours. Inoculate 2 mL of activated bacterial liquid into a 200 mL LB medium conical flask with an inoculation amount of 1%, and add 200 μL of ampicillin, and culture in a constant temperature shaker at 37℃, 220 rpm. When the bacterial growth reaches OD600 at about 0.6, add 100 μL of isopropyl-β-D-thiogalactopyranoside (IPTG) solution to the LB medium, and culture at 16℃, 160 rpm for 16 hours. Centrifuge the culture at 4℃, 8000 rpm for 15 min, and collect the bacterial cells. Resuspend the bacterial cells with PBS, centrifuge and wash twice again, weigh the bacterial cells, and store them in a refrigerator at -20℃. Dissolve about 20 mL of PBS per 1 g of bacterial cells, and sonicate the bacteria at 180 W for 25 min with a frequency of 3 s on and 5 s off. Then centrifuge at 4℃, 10000 rpm for 20 min. Take a small amount of whole bacterial liquid before centrifugation, the precipitate and supernatant after centrifugation. The supernatant is filtered through a 0.45 μm filter membrane and then purified through an AKTA prime protein purification system.
[0045] 2. Reagents 1) LB medium: 10 g tryptone, 5 g yeast extract, 10 g NaCl. Add about 900 mL of deionized water, adjust pH to 7.4, make up to 1 L, after dispensing, sterilize in a high-pressure steam sterilizer at 121 °C for 20 min. Solid medium is added to 15 g of agar powder per liter of liquid medium after dispensing, and sterilized by high-pressure steam.
[0046] 2) PBS solution: 0.14 mol NaCl (8.18 g), 3 mmol KCl (0.22 g), 0.01 mol Na2HPO4 (1.42 g), 2 mmol KH2PO4 (0.27 g) are dissolved in about 900 mL of deionized water, adjust pH to 7.4, make up to 1 L, sterilize in a high-pressure steam sterilizer at 121 °C for 20 min.
[0047] 3) 0.5 mol / L IPTG inducer: 0.12 g IPTG is dissolved in 1 mL of deionized water; after filtration with a 0.22 μm filter, store in a -20 °C refrigerator.
[0048] 4) 100 mg / mL Amp solution: 100 mg of ampicillin is dissolved in 1 mL of deionized water; after filtration with a 0.22 μm filter, store in a -20 °C refrigerator.
[0049] 5) Equilibrium buffer (50 mmol / L imidazole buffer): 0.5 mol NaCl (29.22 g), 0.01 mol Na2HPO4 (1.4196 g), 0.01 mol NaH2PO4 (1.1998 g), 50 mmol imidazole (3.404 g) are dissolved in 900 mL of deionized water, adjust pH to 7.4, make up to 1 L, sterilize at 121 °C for 20 min.
[0050] 6) Elution buffer (500 mmol / L imidazole buffer): The equilibrium buffer with an imidazole concentration of 500 mmol (34.04 g) is sterilized at 121 °C for 20 min.
[0051] 3. Construction of plasmids and expression and purification of proteins The amino acid sequences of human CXCL-1 and PD-L1 were optimized for eukaryotic (human) expression and gene synthesis. The synthesized gene fragments were subcloned into the eukaryotic expression vector pcDNA3.1-N-GST-TEV. The recombinant proteins were produced by the HEK-293F cell protein expression system and purified using a GSTrap FF chromatography column and an AKTA primer plus (GE Healthcare) affinity chromatography. The basic principle of purification is that the GST tag on the surface of the protein forms a coordination interaction with the reduced glutathione covalently bound to the chromatography column, so that the target protein is adsorbed on the chromatography column. The protein is separated from the protein mixture, and then the target protein is eluted by high-concentration reduced glutathione.
[0052] The 2C-KN, KN-2C, 12D-KN, KN-12D, 3E-KN, and KN-3E total six bispecific nanobodies (amino acid sequences are shown above) were optimized for prokaryotic (E. coli) expression of the amino acid sequence. The nanobody sequence was synthesized by Shenguo Bioengineering (Shanghai) Co., Ltd. and cloned into the prokaryotic expression vector pET-32a (+), with a His tag linked to the C-terminal of the antibody. The plasmid was introduced into Trans B engineering bacteria for protein expression. After fermentation, the cells were ultrasonically broken to extract the supernatant, which was purified by an AKTA prime protein purification system and a 5 mL His Trap TM HP pre-packed column for affinity chromatography purification to obtain the corresponding nanobodies.
[0053] The purification process is as follows: 1) The instrument is rinsed with deionized water filtered with a 0.45 μm filter membrane through the water washing program of the instrument to remove ethanol from the instrument.
[0054] 2) Install a 5 mL nickel ion affinity chromatography column on the instrument, and rinse the column with deionized water to remove ethanol until the indicator lines remain stable at the baseline position, about 50 mL of deionized water.
[0055] 3) Rinse the column with equilibration buffer at a flow rate of 5 mL / min until the lines are flat, about 70 mL of equilibration buffer.
[0056] 4) Load at a flow rate of 1 mL / min and collect the breakthrough peak. After loading is complete, first rinse with equilibration buffer at a flow rate of 1 mL / min to allow the sample to flow through the chromatography column, and then equilibrate the column at a flow rate of 4 mL / min.
[0057] 5) Wash the protein with elution buffer at a flow rate of 4 mL / min, and collect the elution peak. At this time, the protein in the elution peak is the nanobody.
[0058] 6) After all the bound proteins are eluted, rinse with DI water until the salt ion concentration is back to zero.
[0059] 7) Rinse with 50 mL 20% ethanol, make sure the column is fully immersed in ethanol, take down the column, store at 4°C, and turn off the instrument.
[0060] Two bispecific antibodies (amino acid sequences are shown above) of KN-2C-Fc and 12D-KN-Fc were optimized for eukaryotic (human) expression of amino acid sequences, and the nanobody sequences were synthesized by Shenguo Bioengineering (Shanghai) Co., Ltd. and cloned into the eukaryotic expression vector pcDNA3.1. Recombinant proteins were produced by the HEK-293F cell protein expression system, and the supernatant was subjected to affinity chromatography purification using Protein A Sepharose and AKTA prime protein purification system to obtain the corresponding antigen proteins.
[0061] 4. SPR verifies the affinity of nanobodies SPR experiments are commonly used to accurately determine the affinity constant KD of antigen-antibody reactions. The present application uses a Biacore T200 instrument (Cytiva) to measure SPR affinity, the chip model is 4E3 ACM5, and the temperature is 25°C. The purified His-tagged PD-L1 or CXCL1 protein (2 units in 10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% P20) is covalently bound to a CM5 sensor chip, and the immobilization density is about 350 resonance units (RUs). An unrelated biotinylated protein is immobilized on a reference surface with matching RU values to control non-specific binding. By diluting the affinity chromatography and purified nanobodies with BIAcore running buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% (v / v) P20), set the nanobody concentration gradient to 9 times dilution concentrations from 1000 nM / L to 3.90625 nM / L, and select a concentration to repeat the test; Set the program to load, and measure at a flow rate of 30 μL. Then pass the running buffer without nanobodies through the chip to allow spontaneous dissociation at the same flow rate. After each run, inject 10 mm pH 1.5 glycine to regenerate the sensor chip. After the experiment, take off the machine, import the data obtained into the instrument software for analysis, use the 1:1 Langmuir binding model, and calculate the affinity constant K D value after data fitting.
[0062] The detection results are shown in Table 1 and Figures 4-6 .
[0063] Table 1. Interaction between CXCL1 and PD-L1 targeted bispecific nanobodies and PD-L1, CXCL1
[0064] The above description is only the preferred embodiment of the application, and is not intended to limit the application. The application can have various modifications and changes for those skilled in the art. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the application shall be included in the protection scope of the application.
Claims
1. A bispecific nanobody targeting CXCL1 and PD-L1, characterized in that: It includes at least one nanobody that recognizes the target CXCL1 and one nanobody that recognizes the target PD-L1, and the nanobody monomers are connected by a linker; The amino acid sequence of the Nanobody CDR1-CDR3 that recognizes the target CXCL1 is selected from any one of the following combinations: Combination 1, wherein the amino acid sequences of CDR1 to CDR3 are shown as SEQ ID NO. 1 to SEQ ID NO. 3, respectively; Combination 2, the amino acid sequences of CDR1 to CDR3 are shown in SEQ ID NO. 4 to SEQ ID NO. 6, respectively; Combination 3, the amino acid sequences of CDR1 to CDR3 are shown in SEQ ID NO. 7 to SEQ ID NO. 9, respectively; The amino acid sequences of the nanoantibody CDR1-CDR3 that recognizes the target PD-L1 are shown as SEQ ID NO.10 to SEQ ID NO.12, respectively.
2. The bispecific nanobody targeting CXCL1 and PD-L1 according to claim 1, characterized in that The amino acid sequence of the linker is shown in SEQ ID NO.
13.
3. The bispecific nanobody targeting CXCL1 and PD-L1 according to claim 1, characterized in that The amino acid sequence of the bispecific nanobody targeting CXCL1 and PD-L1 is shown in any one of SEQ ID NO.14 to SEQ ID NO.
21.
4. A nucleic acid molecule encoding the bispecific Nanobody targeting CXCL1 and PD-L1 as described in any one of claims 1 to 3.
5. An expression vector, characterized in that comprising the nucleic acid molecule of claim 4; Preferably, the expression vector comprises a bacterial plasmid, a bacteriophage, a yeast plasmid, a plant cell virus or a mammalian cell virus.
6. Transform or transfect a host cell with the expression vector according to claim 5; Preferably, the host cell is a plant cell or a microbial cell.
7. A conjugate or a coupling substance, characterized in that Comprising a chemically labeled or biologically labeled bispecific nanobody targeting CXCL1 and PD-L1 as claimed in any one of claims 1 to 3 and an acceptable excipient or carrier.
8. Use of the bispecific Nanobody targeting CXCL1 and PD-L1 according to any one of claims 1 to 3 or the conjugate or conjugate according to claim 7 in the preparation of an anti-tumor drug; Preferably, the tumor comprises colorectal cancer.
9. Use of the bispecific nanobody targeting CXCL1 and PD-L1 according to any one of claims 1 to 3 or the conjugate or conjugate according to claim 7 in the preparation of a cytokine detection reagent and / or kit.
10. A cytokine detection reagent, characterized in that: It comprises the bispecific nanobody targeting CXCL1 and PD-L1 according to any one of claims 1 to 3 or the conjugate or conjugate according to claim 7 and an acceptable adjuvant and / or carrier.
Citation Information
Patent Citations
PD-l1 binding polypeptide or composite
CN110312736A
Targeting PD-L1 / HSA / CCL5 three-specific nano antibody as well as derivative and application thereof
CN117343194A
Combination of PD-l1 binding molecule and protein-drug conjugate, and use thereof
WO2025113644A1
Composition containing PD-l1 binding molecule and bispecific antibody-drug conjugate and use thereof
WO2025113646A1
Cited By
Anti-CXCL1 nano antibody and application thereof
CN120795145A
A nanobody against CXCL1 and its application
CN120795145B
